Mouse cerebral cortex slices will synthesize
of norepinephrine because it is not blocked by the noradrenergic antagonist d-1-propranolol and is still present in mice in which an 85% depletion of norepinephrine was induced by intracisternal 6-hydroxydopamine injections. Other cortical putative neurotransmitters such as y-aminobutyric acid, aspartic acid, glutamic acid, somatostatin, and acetylcholine (tested with the agonist carbamylcholine) do not induce a breakdown of [3H] glycogen. This glycogenolytic effect of VIP and norepinephrine, presumed to be mediated by cyclic AMP formation, should result, at the cellular level, in an increased glucose availability for the generation of phosphate-bound energy. Given the narrow radial pattern of arborization of the intracortical VIP neuron and the tangential intracortical trajectory of the noradrenergic fibers, these two systems may function in a complementary fashion: VIP regulating energy metabolism locally, within individual columnar modules, and norepinephrine exerting a more global effect that spans adjacent columns.
in glial cells and in neurons (21, 22) . A large number of studies have been published with regard to the various aspects of glycogen metabolism in glial and neuronal elements (23) (24) (25) (26) (27) (28) . Furthermore, in a series of elegant biochemical and autoradiographic studies, Wolfe and Nicholls (29) have shown that a mechanism for ['4C]glucose uptake and the subsequent synthesis of ['4C]glycogen existed in glial cells and neurons of the leech central nervous system. They also showed that this uptake and synthesis process could take place in neurons deprived of their glial environment (29) . More recently, Quach et aL (30) have developed a sensitive method by which the effects of putative neurotransmitters on [3H]glycogen levels newly synthesized from [3H]glucose can be monitored in brain slices.
Here we report that VIP induces a concentration-dependent hydrolysis of newly synthesized [3H]glycogen in mouse cortical slices. This effect is independent of and 20 times more potent than the glycogenolytic action of norepinephrine (30), confirmed by us in this study. The presence of two independent transmitters mediating glycogenolytic responses in cerebral cortex, similar to their action in the periphery, may indicate that hormones regulating energy metabolism systemically also may regulate this function within precise anatomical domains ofthe central nervous system.
Vasoactive intestinal peptide (VIP) is a 28-amino acid polypeptide first isolated from porcine intestine by Said and Mutt (1) . It shares structural homologies with other gastrointestinal peptides, such as glucagon, secretin, and gastric inhibitory peptide (2) . Its spectrum of biological activities includes systemic vasodilation, increased cardiac output, and hyperglycemia (1) ; smooth muscle relaxation (3); some differential effects on secretory processes in the gastrointestinal tract (4-6); and glycogenolysis in liver slices (7) . VIP-immunoreactive material has been identified in the nervous system (8) (9) (10) (11) , the highest concentration being in cerebral cortex (9, 11) ; neurons with VIPlike immunoreactivity have been visualized in the central nervous system (10) (11) (12) (13) . In addition to its presence in neurons, other criteria for attributing a possible neurotransmitter function to VIP include its localization in (14) and potassium-induced release from (14, 15) synaptosomal preparations. Furthermore, specific recognition sites for radiolabeled VIP have been demonstrated in rat (16) and guinea pig (17) brain membranes, and a VIP-stimulated adenylate cyclase has been identified in various areas of the central nervous system (18, 19) .
Glycogen is the single largest energy reserve in the brain (20) . It can be visualized by light and electron microscopy both MATERIALS AND METHODS Animals. Young adult male Swiss albino mice (18-20g) were used throughout the study. They were housed six per cage and maintained in an alternating light/dark cycle (12:12 hr) with free access to food and water.
Tissue Preparation and Incubations. The method described by Quach et al (30) was used: mice were killed by decapitation, the brain quickly was removed, the cerebral cortex was dissected on ice and placed in a modified Krebs-Ringer bicarbonate buffer (120 mM NaCl/5 mM KCV2. content of the slices increased linearly during 30 min of incubation, at which time the rate of synthesis decreased and a plateau was eventually reached (Fig. 1) . Addition of 1.0 ,.&M VIP after 30min of incubation induced a rapid fall in the [3H]glycogen content (Fig. 1) . This glycogenolytic action of VIP was concentration-dependent (Fig. 2) . The Eadie-Hofstee plot of the dose-response curve shown in Fig. 2 (Table 2) . Carbamylcholine, a cholinergic agonist, was similarly inactive (Table 2) . Preliminary results indicate that somatostatin does not antagonize the glycogenolytic effect induced by VIP (not shown).
Interactions Between VIP and Norepinephrine. The decrease in [3H]glycogen levels induced by ,uM norepinephrine was effectively blocked (P < 0.01) by 10 ,uM d-l-propranolol, a -adrenergic antagonist (Table 1) . In contrast to this result, d-l-propranolol did not antagonize the glycogenolytic action of 0.1 tM VIP ( Table 1) . The /&adrenergic blocker did not affect the [3H]glycogen levels when tested alone (Table 1) .
No significant difference in the glycogenolytic effect of 0.1
AtM VIP was apparent between mice in which an 85% depletion in cortical norepinephrine was induced by intracisternal 6-hyroxydopamine injections and control mice (Fig. 3) . Finally, VIP and norepinephrine tested. together at supramaximal concentrations showed no additive effects (Table 1) .
DISCUSSION
We have studied the effects of various cortical putative neurotransmitters on the levels of [3H]glycogen newly synthesized from [3H]glucose in vitro by mouse cortical slices. The identity with [3H]glycogen ofthe 3H-labeled product isolated by ethanol precipitation is demonstrated by its solubility properties and by its sensitivity to amyloglucosidase.
Among the various putative neurotransmitters tested, only VIP and norepinephrine had an effect on [3H]glycogen levels: they induced a concentration-dependent hydrolysis of the newly synthesized 3H-labeled polysaccharide. The EC50 for this effect was 26 nM for VIP and 500 nM for norepinephrine. The maximal [3H]glycogen hydrolysis induced by both neurotransmitters was 75-80% of basal levels. Secretin, a structural homolog of VIP, at 500 nM induced a significant decrease in [3H]glycogen levels.
The preparation used consists of cortical slices 250 Am in section and approximately 1500 Aum in length (depth ofcortex).
Therefore, in these slices a number ofcell bodies and processes are intact and some local contacts may be maintained. At this level of neuronal organization, therefore, an effect observed with one neurotransmitter could be mediated by the release of another. Because norepinephrine displays a glycogenolytic action (ref. 30 ; this report), we tested the possibility that the effect ofVIP on [3H]glycogen levels was mediated by norepinephrine release. Two sets of experiments demonstrated that this could not account for the VIP. effect. First, d-1-propranolol, a /&ad-renergic antagonist, effectively antagonized the action of norepinephrine but not that of VIP (Table 1) . Second, in mice whose noradrenergic cortical innervation was reduced by 85% by 6-hydroxydopamine, VIP had the same glycogenolytic effect as in control mice.
Other putative neurotransmitters present in cortex (36) Secretin is structurally related to VIP (2); therefore, its glycogenolytic action, observed only at rather high concentrations for a peptide (Table 2) , may be a consequence of an interaction with VIP receptors. However, a direct interaction of secretin with specific secretin receptors cannot be excluded, particularly in view of the fact that this peptide has been demonstrated to stimulate cyclic AMP formation in cultured mouse brain cells through receptors separate from those for VIP (43) . Although a secretin-like bioactive material has been extracted from pig brain (44) , a clear neurotransmitter function has not yet been attributed to this unidentified peptide.
It should be noted here that Quach et aL have reported the glycogenolytic action of two other monoamines-namely histamine and serotonin (30) . Interestingly, in analogy to the coeruleo-cortical noradrenergic projection (45) (46) (47) , both the serotonergic (48, 49) and possibly histaminergic (50) ascending projections are highly divergent circuits, originating from relatively small nuclei in the brain stem and projecting widely -throughout the cerebral cortex.
A common feature that distinguishes norepinephrine and VIP from other cortical neurotransmitters is their ability to stimulate the membrane-bound enzyme adenylate cyclase (18, 19, 51) . This action suggests a possible molecular mechanism responsible for the glycogenolytic action of the two substances. Quach et aL have demonstrated that the effect of norepinephrine on [3H]glycogen levels was potentiated by the phosphodiesterase inhibitor isobutylmethylxanthine and mimicked by dibutyryl-cyclic AMP (30) . In our studies, the effect ofVIP also was potentiated by isobutylmethylxanthine (not shown), suggesting that the glycogenolytic action of the peptide was mediated by cyclic AMP. In peripheral tissues (52), brain (23, 24) , neuroblastoma, and astrocytoma cell lines (25, 26) , cyclic AMP activates phosphorylase through a cascade of enzymatic phosphorylation steps, thus initiating glycogen degradation. This process, along with the inhibition of glycogen synthetase (26) , ultimately results in a decrease in the cellular glycogen content. However, a calcium-mediated phosphorylase activation mechanism exists in muscle (53) , and cyclic AMP-independent glycogenolysis also has been observed in astrocytoma and neuroblastoma cell lines (26) . The effects of calcium on the glycogenolytic action of VIP may. be difficult to determine, given the important role of this cation in adenylate cyclase activity regulation (54) .
Glycogen hydrolysis induced by the two cortical neurotransmitters, will result in an increased glucose availability for the generation of phosphate-bound energy in those cellular elements receiving terminals from VIP and norepinephrine neurons. This similar action of the two neurotransmitters at the cellular level is particularly interesting, given the neuronal organization of the cortical noradrenergic and VIP systems. A major feature of the intracortical trajectory of the ceruleo-cortical noradrenergic projection is its tangential organization (45) (46) (47) . This tangential pattern of organization stands in striking contrast with the strictly radial orientation of the intracortical VIP neuron (11, 55) . Recently, we have extended (55) the studies ofother investigators (10-13) on the immunohistochemical characterization ofthe VIP neurons within the cerebral cortex. Our observations indicate that the processes of an individual VIP neuron extend across the entire vertical thickness ofthe cerebral cortex, arborizing in a narrow radial column with minimal branching in the horizontal plane. This orthogonal pattern of organization, confers upon the VIP neuron the capacity to regulate energy metabolism locally, within individual columnar modules. This anatomical profile contrasts with the coeruleocortical noradrenergic projection, which has the capacity to exert its metabolic actions more globally, throughout a vast expanse of cortex.
A final observation can be made: VIP and norepinephrine display similar glycogenolytic actions in peripheral tissues. This action may indicate that certain substances with specific hormonal roles in several cell systems may exert similar homeostatic functions at the cellular level within the central nervous system, which are constrained by the spatiotemporal functional precision inherent to neural transmission.
